Business Wire

PPD Expands GMP Lab Testing Capabilities for Biologics

Jaa

Pharmaceutical Product Development, LLC (PPD) is adding gene and cell therapy analytical testing to its GMP (good manufacturing practices) laboratory in Athlone, Ireland, to support the pharmaceutical industry’s growing need for biologics testing. The enhancements in PPD® Laboratories’ Athlone location complement the ongoing capacity and capability expansions at its flagship GMP lab in Middleton, Wisconsin, enabling the company to expand the global reach of its industry-leading biologics testing services.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181206005625/en/

PPD® Laboratories’ Athlone GMP lab (Photo: Business Wire)

PPD® Laboratories’ Athlone GMP lab (Photo: Business Wire)

“PPD Laboratories has been focused on providing cutting-edge gene and cell therapy analytical testing services and capabilities around the world,” said Jon Denissen, Ph.D., senior vice president of the company’s bioanalytical and GMP labs. “These changes in Athlone are part of our ongoing plan to ultimately mirror there the upgrades we’ve been incorporating in Middleton. Our goal is to offer the same extensive biologic, gene and cell therapy portfolio to clients in both Europe and North America, giving them additional opportunity to bring their valued assets to our scientific professionals at either GMP location.”

The GMP lab expansion will add nearly 6,000 square feet (540 square meters) of new lab space to the existing 41,000 square feet (3,850 square meters) at the Athlone facility. The new space will be primarily devoted to biologics testing and will enable the company to add quantitative polymerase chain reaction (qPCR) platforms for contaminant testing for biologics, which is a new capability for the Athlone location. The company anticipates adding about 20 positions as a result of the expansion.

PPD Laboratories’ GMP lab is a leading provider of chemistry, manufacturing and controls (CMC) laboratory services for all phases of drug development.

The Athlone GMP lab offers fully integrated solutions for pharmaceutical product development, including analytical testing services, stability testing, quality control and release testing. In addition to biologic testing, the laboratory is a market leader in the analysis of small molecule and inhalation products, as well as extractables and leachables testing.

In addition to the GMP labs in Athlone and Middleton, PPD Laboratories’ operations also include a bioanalytical lab in Middleton; vaccine sciences, bioanalytical and biomarker labs in Richmond, Virginia; central labs in Shanghai, China; Brussels, Belgium; Highland Heights, Kentucky; and Singapore; and a biomarker lab in Highland Heights.

About PPD
PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 47 countries and approximately 20,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health. For more information, visit www.ppdi.com.

Contact information

Media:
Randy Buckwalter
+1 919 456 4425
randy.buckwalter@ppdi.com

Investors:
Nate Speicher
+1 910 558 6783
nate.speicher@ppdi.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Secure-D Exposes Suspicious Android App with 500 Million Downloads22.5.2019 16:49:00 EESTTiedote

Upstream, a leading mobile technology company, has unveiled that the popular Android application VidMate triggers suspicious background activity. Hidden software within the app delivers invisible ads, generates fake clicks and purchases, installs other suspicious apps without consent and collects personal users’ information. Consequently, it depletes users’ data allowance and brings unwanted charges. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190522005501/en/ With over 500 million downloads reported, VidMate is a popular Android application for streaming and downloading videos and songs from services such as Dailymotion, Vimeo, and YouTube. It is not available in the Google Play Store but is distributed through third-party app stores like CNET or Uptodown. According to publicly available information, VidMate was developed by a subsidiary of UC Web, which is owned by Chinese conglomerate Alibaba. Over a recent period Upst

Airship’s Data Study Reveals the State of Global Mobile Permissions One Year into GDPR22.5.2019 16:35:00 EESTTiedote

With GDPR reaching its one year anniversary May 25, customer engagement company Airship today revealed top-level results of its global benchmark study, examining the state of mobile app user permissions across nearly 700 million people worldwide. While marketers trimmed customer lists to meet new regulatory requirements for "traditional" channels (i.e., email), mobile app audiences continue to grow — up globally by +16.6 percent year over year. Businesses are also sending more notifications — averaging 36 per user per month (up 18.4 percent since last year) — while the average notification opt-in rate remains high at over two-thirds (67 percent) of global app users. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190522005486/en/ With mobile app audiences growing around the world, businesses are more heavily leveraging notifications with negligible impact to opt-in rates. (Graphic: Business Wire) These metrics vary at a regio

Diligent Launches Modern Governance to Address Dangerous Governance Deficits and Announces New Modern Governance Summit22.5.2019 16:27:00 EESTTiedote

Today, Diligent Corporation launched a new category, called modern governance, designed to provide leaders with the missing key to bring governance into the digital age, along with new technology and a summit to support this well-designed system. Modern governance is the practice of empowering leaders with technology, insights, and processes to fuel good governance that organizations require to thrive and endure. Modern governance helps organizations address governance deficits. A governance deficit means an organization lacks the security, foresight, and accountability to withstand the onslaught of contemporary challenges – such as activist investors, cyber risk, regulation, diversity and global uncertainty. Feedback from Diligent’s 16,000 clients and the 600,000 leaders who use its technology – including more than 50% of the Fortune 1000, 70% of the FTSE 100, and 65% of the ASX – sparked the need for rethinking how companies and their boards should approach governance to navigate tod

Wipro Builds a Blockchain-Based Solution for Travacoin to Enable Digital Currency-Based Payments for the Airline Industry22.5.2019 15:19:00 EESTTiedote

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting, and business process services company, today announced that it has developed a blockchain-based payment solution for Travacoin, a company specializing in an eponymous digital payment solution. Travacoin is a digital payment system which enables airlines to refund and compensate passengers in a timely manner when a disruption occurs. Passengers will be notified of a delay or cancellation and refunded in this digital currency, which can be used to repurchase airline tickets, book hotels and avail other airport and travel related services. Passengers will benefit by way of a significant reduction in the waiting time for compensation. In addition, passengers can use Travacoins at retail stores in and around the airport and avail attractive discounts offered by retail partners. By compensating passengers with Travacoins, airlines will be able to reduce their administrative overheads and

New Fluid Dispensing Guide for Stock Lubrication and Metal Stamping from Nordson EFD22.5.2019 15:15:00 EESTTiedote

Nordson EFD , a Nordson company (NASDAQ: NDSN), the world’s leading precision fluid dispensing systems manufacturer, has released a new solutions guide for stock lubrication and metal stamping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190522005010/en/ The Stock Lubrication Solutions Guide is an overview of how Nordson EFD’s MicroCoat® lubrication system provides more consistent oil coverage and significantly reduces oil waste by up to 90%. By doing so the system quickly pays for itself by extending tool life and reducing oil usage, thus lowering waste disposal costs. In the guide, eight MicroCoat customers share application details that illustrate the benefits of the system’s Low Volume Low Pressure (LVLP) technology. Each customer has a different application with different problems to solve. “Our MicroCoat system is truly the first stock lubrication system to provide consistent oil coverage without overspray,” said Cl

Altasciences Leads Research on Chemical Nerve Agent Therapeutic from Preclinical to Clinical Phase I22.5.2019 15:04:00 EESTTiedote

Altasciences announced today that they have been selected by Leidos Health to guide and support the development of RAP-103 peptide as a chemical nerve agent therapeutic on behalf of the Medical CBRN Defense Consortium and funded by the Defense Threat Reduction Agency (DTRA). Altasciences will conduct the required Safety Testing, all IND-enabling studies (non-GLP and GLP), the necessary Phase I clinical trials, and associated bioanalytical analysis. “Altasciences’ preclinical and clinical teams are collaborating with Leidos Health on this important program. Together, we have developed a plan to move RAP-103 from preclinical, safely through early clinical trials. As a mid-size CRO specializing in a flexible, innovative approach to providing comprehensive early stage drug development, we have the experience and team in place to complete this program successfully, on time and within budget,” explained Steve Mason, Vice President, Site Operations, at Altasciences. For over 25 years, Altasci

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme